1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
- Author
-
Martínez López, Joaquín, De La Cruz, Javier, Gil Manso, Rodrigo, Alegre Amor, Adrián, Ortiz, Javier, Llamas, Pilar, Martínez Díez, Yolanda, Hernández Rivas, José Ángel, González Gascón y Marín, Isabel, Benavente Cuesta, Celina, Estival Monteliu, Pablo, Jiménez Yuste, Víctor, Canales Albendea, Miguel Ángel, Bastos Oreiro, Mariana Beatriz, Kwon Kim, Mi, Valenciano, Susana, Callejas Charavia, Marta, López Jiménez, Javier, Herrera Puente, Pilar, Duarte, Rafael, Núñez Martín Buitrago, Lucía, Sánchez Godoy, Pedro, Jacome Yerovi, Cristina, Martínez Barranco, Pilar, García Roa, María, Escolano Escobar, Cristian, Matilla García, Arturo, Rosado Sierra, Belén, Aláez Usón, María Concepción, Quiroz Cervantes, Keina, Martínez Chamorro, Carmen, Pérez Oteyza, Jaime, Martos Martinez, Rafael, Herráez, Regina, González Santillana, Clara, Del Campo, Juan Francisco, Alonso, Arancha, Fuente, Adolfo de la, Pascual, Adriana, Bustelos Rodriguez, Rosalía, Sebrango, Ana, Ruiz Mediavilla, Elena, Marcheco-Pupo, Eriel Alexis, Grande, Carlos, Cedillo, Ángel, Lumbreras Bermejo, Carlos Juan, Arroyo Barea, Andrés, Casas Rojo, Jose Manuel, Calbacho Robles, Maria, Díez Martín, José Luis, García Suárez, Julio, Martínez López, Joaquín, De La Cruz, Javier, Gil Manso, Rodrigo, Alegre Amor, Adrián, Ortiz, Javier, Llamas, Pilar, Martínez Díez, Yolanda, Hernández Rivas, José Ángel, González Gascón y Marín, Isabel, Benavente Cuesta, Celina, Estival Monteliu, Pablo, Jiménez Yuste, Víctor, Canales Albendea, Miguel Ángel, Bastos Oreiro, Mariana Beatriz, Kwon Kim, Mi, Valenciano, Susana, Callejas Charavia, Marta, López Jiménez, Javier, Herrera Puente, Pilar, Duarte, Rafael, Núñez Martín Buitrago, Lucía, Sánchez Godoy, Pedro, Jacome Yerovi, Cristina, Martínez Barranco, Pilar, García Roa, María, Escolano Escobar, Cristian, Matilla García, Arturo, Rosado Sierra, Belén, Aláez Usón, María Concepción, Quiroz Cervantes, Keina, Martínez Chamorro, Carmen, Pérez Oteyza, Jaime, Martos Martinez, Rafael, Herráez, Regina, González Santillana, Clara, Del Campo, Juan Francisco, Alonso, Arancha, Fuente, Adolfo de la, Pascual, Adriana, Bustelos Rodriguez, Rosalía, Sebrango, Ana, Ruiz Mediavilla, Elena, Marcheco-Pupo, Eriel Alexis, Grande, Carlos, Cedillo, Ángel, Lumbreras Bermejo, Carlos Juan, Arroyo Barea, Andrés, Casas Rojo, Jose Manuel, Calbacho Robles, Maria, Díez Martín, José Luis, and García Suárez, Julio
- Abstract
Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis., Fundación Madrileña de Hematología y Hemoterapia, Fundación Leucemia y Linfoma, Asociación Madrileña de Hematología y Hemoterapia, Depto. de Medicina, Fac. de Medicina, TRUE, pub
- Published
- 2023